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After incubation of H9 cells infected with human immunodeficiency virus (HIV) with pepstatin A at 10m4 M for 2, 4, 
or 11 days, the culture medium contained significantly less HIV core antigen (~24) than controls without pepstatin A 
and no or only borderline activity of reverse transcriptase was detected. In addition, after pepstatin A treatment no 
infectious HIV at 2 or 4 days and only minimal amounts at 11 days were detectable in the culture medium. 
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1. INTRODUCTION 
Virus-encoded enzymes are suitable targets for 
antiviral therapy because most of these enzymes 
have a more restricted range of substrate specificity 
than their cellular or extracellular counterparts. 
The functions of the viral enzymes are limited to 
the replication cycle of the virus, and agents 
specifically inhibiting viral-encoded enzymes 
should not impair cellular functions. 
Retroviral proteases, first described in avian and 
murine retroviruses [1,2], process their viral gag 
(and gag-pol) protein precursors but not other pro- 
teins (unless they are denatured). Processing of the 
viral (gag-pol) protein precursors is necessary for 
the production of infectious virus. 
Before searching for suitable inhibitors of retro- 
virus-encoded proteases, the active site of the en- 
zyme had to be identified. A conserved Asp-Thr- 
Gly sequence present in the amino acid sequences 
of retroviral proteases suggested that such pro- 
teases are aspartic-type proteases [3-51 (and a 
structural dimer model for viral aspartic proteases 
was recently proposed [4]). Further, it was reported 
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that the viral-encoded proteases of bovine 
leukemia virus (BLV), murine leukemia virus 
(MLV) and human T cell leukemia virus (HTLV I) 
could be inhibited in vitro by pepstatin A [6], an 
aspartic protease inhibitor [7]. Recent site-specific 
mutagenesis of Asp-25 proved that the HIV pro- 
tease has an aspartic proteolytic site [S-lo], and it 
was demonstrated that pepstatin A but not some 
other substances known to block aspartic proteases 
inhibited in vitro the HIV protease [lo-121. In 
checking whether pepstatin A also inhibited in vivo 
the HIV gag processing in cell cultures, we found 
that intracellular gag processing was partially in- 
hibited [lo], and we have now extended these ex- 
periments in HIV-infected cultured cells, studying 
the inhibitory effect of pepstatin A on viral antigen 
production, on the formation of active reverse 
transcriptase RT and on the production of infec- 
tious HIV. 
2. MATERIALS AND METHODS 
2.1. Cells and virus 
H9 cells were grown in RPM1 1640 supplemented with 20% 
fetal calf serum (FCS) at 37°C in air plus 5% COa. Human im- 
munodeficiency virus (HIV strain III B) was propagated in H9 
cells; the supernatant of infected cultures with an infectivity titer 
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of 1@.5 TCIDsa/ml was used as virus stock (H9 cells and HIV 
were kindly supplied by Dr R. Gallo). 
2.2. HIV infectivity assay 
Undiluted and serially diluted test materials (0.1 ml for stock 
virus titration or 0.5 ml for evaluation of experimental cultures) 
were added to lo6 H9 cells in 1 or 0.6 ml culture medium, 
respectively, in microtiter plates and incubated with a medium 
renewal after 5 days. Supernatants were checked for virus 
replication by determining HIV core antigen (CA(p24)) and 
reverse transcriptase (RT) activity on the days indicated in table 
1. HIV CA(p24) was determined after detergent lysis using a 
commercially available antigen capture assay (Abbott 
Laboratories, North Chicago). RT was measured as described 
1131. 
2.3. Pepstatin A 
Pepstatin A (Boehringer, Mannheim or Bachem, Switzerland) 
was dissolved in DMSO (Merck, Darmstadt) at a concentration 
of lo-’ M. This solution was added very slowly to cell culture 
medium, with constant stirring to prevent precipitation, to a 
final concentration of 10e4 M. 
2.4. Protocol for determining inhibition of HIV replication by 
pepstatin A 
Aliquots of lo6 H9 cells were suspended in 1 ml medium con- 
taining 10e4 M pepstatin A in 24-well microtiter plates and were 
infected with 10°.5, 1O’.5 or 1O2.5 TCIDsc of HIV in 0.1 ml 
culture medium: duplicate cultures per virus concentration were 
used. The cultures were incubated at 37°C and 80% of the 
culture medium was renewed aily until day 4 and every second 
day thereafter with 50% conditioned medium (by non-infected 
H9 cells) and 50% fresh medium both containing 10e4 M 
pepstatin A to counteract a possible decay of the inhibitor, 
although the exact half-life of the activity of pepstatin A at 37°C 
is unknown. HIV CA(p24), RT activity, and infectious virus 
present in the supernatants were determined after various in- 
cubation periods (see table 1). 
3. RESULTS AND DISCUSSION 
The experiments were designed to test the in- 
hibitory effect of pepstatin A (i) on the production 
of viral antigen, (ii) on the formation of active RT, 
and (iii) on the production of infectious HIV (table 
1). As pepstatin A is relatively water insoluble, it 
was dissolved in DMSO and then diluted very 
carefully into the medium to a maximal concentra- 
tion of 10e4 M. The concentration of 1% DMSO in 
the culture medium (resulting from the dilution of 
the stock solution) did not affect virus propagation 
(not shown), and 10e4 M pepstatin A did not ap- 
pear to be toxic for HIV-infected H9 cells, as had 
been previously discussed [lo]. 
To determine whether the inhibitory effect of 
pepstatin A changed with the length of treatment, 
we evaluated the effect after incubation of the cell 
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cultures for 2, 4 or 11 days with 10e4 M pepstatin 
A. The dependence of the inhibitory effect on the 
titer of the HIV inoculum was tested by using three 
different concentrations of virus inoculum. 
This study confirms our previous observation 
[lo] that pepstatin A inhibits the proteolytic pro- 
cessing of the HIV gag precursor in cultured cells; 
in addition, the studies are extended by the 
demonstration that pepstatin A inhibits the pro- 
duction of infectious HIV in cell cultures. 
No RT activity was detected throughout the en- 
tire experimental period in the pepstatin A- 
containing cultures, not even with the highest 
titered HIV inoculum. The production of CA(p24) 
was substantially reduced or undetectable, de- 
pending on the HIV inoculum and the length of in- 
cubation. 
The supernatants of infected cultures were also 
titrated for infectious virus after 2,4 and 11 days of 
incubation. No infectious virus was detected in the 
culture medium of 10m4 M pepstatin A-containing 
cultures after 2 or 4 days of incubation, and only 
low titers of HIV (lo’.’ TCID&ml) were observed 
after 11 days of incubation in media of cultures 
originally infected with the highest itered virus in- 
oculum (1O2.5 TCID&. Cultures originally in- 
fected with lo’.’ TCIDso showed only borderline 
values at this time. 
The results reported in this paper are interesting 
because pepstatin A is hydrophobic and it was 
uncertain whether it would penetrate cells [14], 
although it has been reported to enter cells and ac- 
cumulate in organelles [151. Three possibilities can 
be envisioned for the site of inhibition; first, 
pepstatin A may permeate into HIV-infected cells, 
and thus inhibit the HIV protease intracellularly. 
Second, it may act at the cytoplasmic membrane, 
blocking maturation of the gag and gag-pol precur- 
sor, thereby preventing virus particle assembly and 
release, and possibly also activation of RT. The se- 
cond possibility is more likely, because studies of 
the topology of gag (-pol) processing of Rauscher 
and Moloney MLV [ 161 suggested the membrane as 
a maturation site. Third, pepstatin A may act ex- 
tracellularly on released but immature virus par- 
ticles. In this case, the maturation of immature 
virus particles released during the first cycle of 
virus replication would be prevented by pepstatin 
A. Such extracellular maturation would occur 
through viral protease within the released particles. 
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Table 1 
Infection of H9 cells with different concentrations of HIV, with (A) and without pepstatin A (B) 
HIV 
inoculum 
TCIDso 
2 
CA(p24) antigena, 
days post-infection 
4 
Infectious HIVb, RT activity, 
days post-infection 10 days post-infection 
rA 
11 2 4 11 ratio -’ 
dA 
cpm* 
A 
102.5 o.339e 0.191 1.974 <0.3 <0.3 1.5 1.7 1881 
0.367 0.119 >2.0 <0.3 <0.3 1.5 0.95 1634 
lo’.5 0.095 0.068 1.396 <0.3 <0.3 so.3 4.1 3792 
0.081 0.061 0.068 f <0.3 <0.3 1.6 1681 
loo.5 0.051 0.054 0.059 <0.3 <0.3 <0.3 1.8 1625 
0.051 0.054 0.001 <0.3 <0.3 <0.3 1.5 1649 
no HIV 0.053 0.053 0.051 <0.3 <0.3 <0.3 1.4 1573 
0.054 0.050 0.051 <0.3 <0.3 <0.3 
cut off 0.098 
B 
102.5 0.712 >2.0 >2.0 >2.5 
0.681 >2.0 >2.0 >2.5 
lo’.5 0.130 1.936 >2.0 1.5 
0.104 > 2.0 >2.0 1.5 
loo.5 0.056 0.341 >2.0 <0.3 
0.055 0.329 >2.0 <0.3 
no HIV 0.050 0.054 0.051 
0.050 0.059 0.124 
cut off 0.098 
a A of the antigen capture assay; mean values of duplicate assays 
b Infectious HIV log TCIDso/ml 
c Ratio of incorporated [‘HITTP with poly dA:dT over poly dA:dT 
>2.5 >2.5 15.7 17859 
>2.5 >2.5 9.0 10151 
>2.5 >2.5 9.3 12685 
>2.5 >2.5 16.3 17445 
2.0 >2.5 33.5 35905 
2.0 >2.5 24.0 31424 
1.5 1791 
* cpm of incorporated [‘H]TTP with poly rA : dT template 
’ Results of duplicate cultures 
f Could not be evaluated for technical reasons 
Further virus replication cycles would then not be 
initiated, even if the immature virus particles could 
adsorb to and penetrate new cells. The third 
possibility would require a release of an amount of 
antigen comparable to the non-inhibited control. 
However, we found a significantly reduced amount 
of CA(p24) in the presence of the inhibitor. It is 
conceivable that a combination of membrane and 
extracellular inhibitor action could take place, 
reducing the amount of released CA(p24) con- 
siderably; this would not have been detected under 
our experimental conditions. In these cir- 
cumstances, however, because antibodies to 
CA(p24) recognize gag protein precursors, im- 
mature particles would have been detected had they 
been present. 
It is also possible that pepstatin A not only 
blocks the virus protease but also affects other 
steps in HIV replication: MuLV containing a pro- 
tease defect [ 17,181 or HIV which contains an 
Asp-25 mutant protease 191 produce a significant 
amount of viral antigen. 
Studies continue, in particular to elucidate the 
topology of the protease action and the exact 
mechanism of the inhibition of virus replication in 
this system by pepstatin A. 
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